Scientists Say New Oral GLP-1 Drug May Help Keep Weight Off Long Term

Weight-loss injections such as Wegovy and Mounjaro have rapidly transformed obesity treatment worldwide. In Great Britain alone, an estimated 1.6 million adults used weight-loss medications over the past year, with most obtaining them privately rather than through the public healthcare system.

These injectable GLP-1 medications are highly effective while treatment continues, often producing substantial reductions in body weight. However, research consistently shows that once treatment stops, many patients regain a significant portion of the lost weight, while associated health improvements gradually fade.

Benefits such as lower blood pressure, improved blood sugar regulation, and healthier cholesterol levels frequently decline after discontinuation. This pattern has intensified concerns about how to maintain weight loss safely, sustainably, and affordably over the long term.

High Costs Limit Long-Term Use

In the United Kingdom, a private prescription for Mounjaro may cost roughly £300 per month, placing long-term treatment beyond the financial reach of many households. Because obesity is generally considered a chronic condition, indefinite treatment at such prices is unrealistic for a large portion of patients.

Part of the high cost stems from how these drugs are manufactured and delivered. Current GLP-1 medications are peptide-based compounds, which break down in the digestive tract and therefore must be administered by injection rather than taken orally. They also require specialized injector pens and refrigerated storage.

Producing, transporting, and storing these injectable systems adds significant complexity and expense. As a result, some people never begin treatment, while others stop prematurely because of cost, inconvenience, or treatment fatigue, limiting the long-term effectiveness of obesity care.

A New Oral GLP-1 Option

Orforglipron, marketed in the United States as Foundayo, is a once-daily oral medication that targets the same GLP-1 hormonal pathway as Wegovy. Unlike injectable GLP-1 drugs, however, orforglipron is based on a small-molecule compound rather than a peptide.

Because small molecules can survive the harsh digestive environment of the stomach and intestines, the drug can be swallowed as a pill and does not require refrigeration. Similar to common medications such as statins, ibuprofen, or aspirin, it is also easier and cheaper to manufacture and distribute on a large scale.

In the United States, a monthly supply of orforglipron is priced between approximately US$149 and US$299, compared with more than US$1,000 for a typical monthly supply of Mounjaro. Health analysts suggest that this lower cost could significantly broaden access if insurance providers and healthcare systems adopt the medication widely.

Weight-Loss Effectiveness And Limits

Phase 3 clinical trial data indicate that orforglipron can produce average weight loss exceeding 15% of body weight in adults with obesity. This places its effectiveness broadly in line with results reported for Wegovy, which also targets the GLP-1 system.

However, orforglipron appears somewhat less potent than Mounjaro, which activates both GLP-1 and additional metabolic hormone pathways and has produced approximately 21% body weight loss in clinical studies.

For some individuals with severe obesity or complex metabolic disease, injectable therapies may therefore remain the preferred option. Nevertheless, many experts argue that an oral treatment offering strong — even if slightly smaller — weight-loss effects could prove highly valuable in real-world care.

Ease of use, lower cost, and reduced stigma surrounding pills compared with injections may improve long-term adherence and overall treatment success for many patients.

Can A Pill Prevent Weight Regain?

One of the biggest challenges in obesity medicine is maintaining weight loss after patients discontinue powerful injectable therapies. Once treatment stops, body weight often rises again surprisingly quickly.

Recent clinical data suggest orforglipron may help address this problem. Researchers studied individuals who had already lost at least 5% of their body weight over 72 weeks while taking either Wegovy or Mounjaro and then discontinued the injections.

Participants were then randomly assigned to receive either orforglipron or a placebo tablet for an additional 52 weeks. This allowed researchers to evaluate whether an oral medication could help preserve the weight-loss benefits previously achieved through injections.

Among participants who had originally used Mounjaro, those receiving placebo regained slightly more than half of the weight they had lost within one year. By contrast, patients switched to orforglipron regained only about 26% of their lost weight.

More than two-fifths of individuals in the orforglipron group maintained over 80% of their earlier weight reduction. This suggests that a substantial proportion of the benefits achieved through injections may be preserved through continued treatment with an oral GLP-1 medication.

Similar patterns appeared among participants previously treated with Wegovy. Those assigned placebo regained approximately 62% of their lost weight, whereas individuals taking orforglipron regained only about 21%, suggesting a relatively consistent protective effect.

Across both groups, participants also maintained improvements in blood sugar levels, blood pressure, insulin sensitivity, and cholesterol markers while taking orforglipron. This indicates the medication may help sustain not only weight stability but broader metabolic and cardiovascular benefits.

Early Evidence And Growing Expectations

The maintenance trial involved just over 100 participants in each treatment group, making it relatively small and insufficient to answer all long-term safety or effectiveness questions. Larger and longer studies are currently underway to determine how durable the effects remain over time and to monitor potential side effects more closely.

Like other GLP-1 medications, orforglipron may cause gastrointestinal symptoms such as nausea, vomiting, diarrhea, and digestive discomfort, especially during dose escalation periods. Regulatory agencies are expected to carefully examine these risks, particularly in patients with additional medical conditions.

Even so, early evidence points toward a potentially important new treatment strategy. Patients may eventually use highly potent injectable medications to achieve significant initial weight loss and then transition to a more affordable oral drug to help maintain those results long term.

Regulatory Outlook And Access

Orforglipron has received approval from the U.S. Food and Drug Administration for obesity treatment, and broader rollout is expected to accelerate over the coming year. Insurance companies and employers are now evaluating how to integrate the medication into healthcare coverage plans.

In the United Kingdom, however, orforglipron has not yet been approved for weight management. If it receives authorization from the Medicines and Healthcare products Regulatory Agency, experts anticipate it could become available between late 2026 and early 2027.

Health economists are watching developments closely because a lower-cost oral GLP-1 therapy could potentially reduce pressure on healthcare budgets while dramatically expanding access to evidence-based obesity treatment.

For people living with obesity, orforglipron does not eliminate the importance of sustainable lifestyle changes involving nutrition, physical activity, sleep, and long-term behavioral habits. However, it may offer a more practical and affordable medical tool for maintaining progress.

If ongoing research confirms current findings, oral GLP-1 medications such as orforglipron could significantly reshape future strategies for long-term weight management and metabolic health.